Negative plus negative positive or negative10/10/2023 ![]() During the induction phase, patients received the TKI plus vincristine and dexamethasone in three 28-day cycles, after which the primary end point was assessed, then they proceeded to the consolidation phase which consisted of the TKI plus methotrexate and cytarabine in six 28-day cycles, followed by maintenance therapy with the TKI plus vincristine and prednisone in eleven 28-day cycles, and finally treatment with TKI monotherapy until the completion of the study. Patients were randomly assigned 2:1 to reduced-intensity chemotherapy in combination with ponatinib 30 mg once daily with dose reduction to 15 mg once daily (n = 164) after MRD-negative CR in the induction phase or reduced intensity chemotherapy with imatinib at a starting dose of 600 mg once daily (n = 81). Eligible patients needed to have an ECOG performance status of 2 or less, no history or current diagnosis of chronic, accelerated, or blastic phase chronic myeloid leukemia, and an absence of clinically significant of uncontrolled cardiovascular disease. ![]() PhALLCON enrolled adult patients with newly diagnosed Ph-positive or BCR::ABL1-positive ALL. And we know that complete molecular response matters a lot resistance is driven by the acquisition of the T315I mutation.” “We know that the remission is not long lasting. “Today, TKIs and chemotherapy or steroids are the standard of care in Ph-positive ALL,” Elias Jabbour, MD, a professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, said during the presentation. The median follow-up was 20.0 months (range, 18-24) in the ponatinib arm and 18 months (range, 14-24) in the imatinib arm. Additionally, the MR4 MRD negativity rates at the end of induction regardless of CR assessment were 41.6% vs 20.5%, respectively (RR, 1.94 95% CI, 1.19-3.17 P =. ![]() At the August 12, 2022, data cutoff, patients who received ponatinib (n = 154) experienced an MRD-negative CR at the end of induction, defined as a hematologic CR for at least 4 weeks with MR4 MRD negativity ( BCR::ABL1 ≤.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |